Odajima Susumu, Tanaka Hidekazu, Fujimoto Wataru, Kuroda Koji, Yamashita Soichiro, Imanishi Junichi, Iwasaki Masamichi, Todoroki Takashi, Okuda Masanori, Hayashi Takatoshi, Konishi Akihide, Shinohara Masakazu, Toh Ryuji, Hirata Ken-Ichi
Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine Kobe Japan.
Department of Cardiology, Hyogo Prefectural Awaji Medical Center Sumoto Japan.
Circ Rep. 2021 Aug 13;3(9):511-519. doi: 10.1253/circrep.CR-21-0088. eCollection 2021 Sep 10.
Because the effectiveness of strengthening guideline-based therapy (GBT) to prevent heart failure (HF) rehospitalization of chronic HF patients remains unclear, this study investigated the characteristics of HF patients in the Kobe University Heart Failure Registry in Awaji Medical Center (KUNIUMI) acute cohort. We studied 254 rehospitalized HF patients from the KUNIUMI Registry. Optimized GBT was defined as a Class I or IIa recommendation for chronic HF based on the guidelines of the Japanese Circulation Society. The primary endpoint was all-cause death or first HF rehospitalization after discharge. Outcomes tended to be more favorable for patients who had rather than had not received optimized GBT (hazard ratio [HR] 0.82; 95% confidence interval [CI] 0.57-1.19; P=0.27). Similarly, among New York Heart Association (NYHA) Class IV patients, outcomes tended to be more favorable for those who had rather than had not undergone optimized GBT (HR 0.73; 95% CI 0.47-1.12; P=0.15). Importantly, outcomes were significantly more favorable among NYHA Class IV patients aged <79 years who had rather than had not undergone optimized GBT (HR 0.33; 95% CI 0.14-0.82; P=0.02). Multivariate Cox regression analysis showed that optimized GBT was the only independent factor for the prediction of the primary endpoint. Optimized GBT can be expected to play an important role as the next move for chronic HF patients.
由于强化基于指南的治疗(GBT)预防慢性心力衰竭(HF)患者再次住院的有效性仍不明确,本研究调查了阿波岐医疗中心神户大学心力衰竭登记处(KUNIUMI)急性队列中HF患者的特征。我们研究了KUNIUMI登记处的254例再次住院的HF患者。优化的GBT被定义为根据日本循环学会指南对慢性HF的I类或IIa类推荐。主要终点是全因死亡或出院后首次HF再次住院。接受了而非未接受优化GBT的患者的结局往往更有利(风险比[HR]0.82;95%置信区间[CI]0.57-1.19;P=0.27)。同样,在纽约心脏协会(NYHA)IV级患者中,接受了而非未接受优化GBT的患者的结局往往更有利(HR 0.73;95%CI 0.47-1.12;P=0.15)。重要的是,在年龄<79岁的NYHA IV级患者中,接受了而非未接受优化GBT的患者的结局明显更有利(HR 0.33;95%CI 0.14-0.82;P=0.02)。多变量Cox回归分析表明,优化的GBT是预测主要终点的唯一独立因素。优化的GBT有望作为慢性HF患者的下一步治疗发挥重要作用。